Takeda Pharmaceutical Co Ltd (4502.T) stock: key figures, P/E, revenue and dividend

Health Care · Japan · ISIN JP3463000004

Price

6,115.00 JPY

Market cap

9.56 tn JPY

P/E (2026)

49.83

P/S (2026)

2.12

Dividend yield

3.30 %

Net margin

4.26 %

Return on equity (ROE)

2.45 %

Return on assets (ROA)

1.23 %

Takeda Pharmaceutical Co Ltd financials

Fiscal year	2025	2026
Revenue	4.58 tn JPY	4.51 tn JPY
Gross profit	2.46 tn JPY	2.30 tn JPY
EBIT	627.54 bn JPY	540.45 bn JPY
Net income	107.93 bn JPY	191.76 bn JPY
Diluted EPS – continuing operations	67.35 JPY	122.72 JPY

Full history since 1994, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 15.10.2026. Details in the risk notice.